Who Pays and Why? Costs, Effectiveness, and Feasibility of HIV Treatment as Prevention
نویسندگان
چکیده
منابع مشابه
Who pays and why? Costs, effectiveness, and feasibility of HIV treatment as prevention.
Treatment as prevention (TasP) has been added to the toolbox of human immunodeficiency virus (HIV) prevention technologies, and countries are at different stages of TasP deployment. In this article we review some of the cost implications and summarize effectiveness data from different settings. Also, we reflect on the affordability and feasibility of programmatic deployment as well as the multi...
متن کاملThe costs of caring: Who pays? Who profits? Who panders?
Avastin, a widely used colon cancer drug manufactured by San Francisco-based biotech company Genentech, has proven a somewhat effective treatment for lung and breast cancer when administered at twice the normal dose. In February, the New York Times carried a story about Avastin's extraordinarily high price when used in this alternative way: $100,000 for one year's treatment--a figure fully twic...
متن کاملWho pays for public employee health costs?
We analyze the incidence of public-employee health benefits. Because these benefits are negotiated through the political process, relevant labor market institutions deviate significantly from the competitive, private-sector benchmark. Empirically, we find that roughly 15 percent of the cost of recent benefit growth was passed onto school district employees through reductions in wages and salari...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2014
ISSN: 1058-4838,1537-6591
DOI: 10.1093/cid/ciu300